Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?

7 Feb 2023

Abstract excerpt

// Shakthivel Mani 1 , Abhishek Chatterjee 1 , Archya Dasgupta 1 , Neelam Shirsat 2 , Sridhar Epari 3 , Girish Chinnaswamy 4 and Tejpal Gupta 1 1 Department of Radiation Oncology, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra 410210, India 2 Department of Neuro-Oncology Laboratory, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36749287
DOI: 10.18632/oncotarget.28360

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?PMID 36749287Read ↗

Clinico-radiological outcomes in WNT-subgroup medulloblastomaSemantic proximity Read ↗

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohortsSemantic proximity Read ↗

Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).Semantic proximity Read ↗

Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic InsightsSemantic proximity Read ↗

Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.Semantic proximity Read ↗

The molecular classification of medulloblastomaSemantic proximity Read ↗

Medulloblastoma: WHO 2021 and BeyondSemantic proximity Read ↗

Medulloblastoma in the age of molecular subgroups: a reviewSemantic proximity Read ↗

Medulloblastoma in the Molecular EraSemantic proximity Read ↗

Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified ApproachSemantic proximity Read ↗

[Medulloblastoma].Semantic proximity Read ↗

Adult Medulloblastoma: Clinico-molecular Spectrum, An Institutional ExperienceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.